Published in Gynecol Oncol on April 01, 1983
Sexual functioning morbidity among cancer survivors. Current status and future research directions. Cancer (1985) 1.33
Psychosexual adjustment after vulvar surgery. Obstet Gynecol (1983) 1.19
Psychosexual adjustment following pelvic exenteration. Obstet Gynecol (1983) 0.99
Sexual functioning after treatment of in situ vulvar cancer: preliminary report. Obstet Gynecol (1988) 0.98
Sexual dysfunction and signs of gynecologic cancer. Cancer (1986) 0.97
Radiation Therapy and Psychological Distress in Gynecologic Oncology Patients: Outcomes and Recommendations for Enhancing Adjustment. J Psychosom Obstet Gynaecol (1986) 0.75
The Papanicolaou smear histories of 237 patients with cervical cancer. Med J Aust (1992) 3.22
Distant metastases in epithelial ovarian carcinoma. Cancer (1987) 2.07
Controlled prospective longitudinal study of women with cancer: I. Sexual functioning outcomes. J Consult Clin Psychol (1989) 2.02
Controlled prospective longitudinal study of women with cancer: II. Psychological outcomes. J Consult Clin Psychol (1989) 1.79
Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol (1983) 1.49
Radical vulvectomy and bilateral inguinal lymphadenectomy through separate groin incisions. Obstet Gynecol (1981) 1.44
Human papillomavirus deoxyribonucleic acid in adenocarcinoma and adenosquamous carcinoma of the uterine cervix. Obstet Gynecol (1986) 1.40
The significance of mild squamous atypia on cytology. Aust N Z J Obstet Gynaecol (1995) 1.39
Sexual functioning morbidity among cancer survivors. Current status and future research directions. Cancer (1985) 1.33
Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors. A review of 74 cases. Cancer (2000) 1.25
Breast cancer surgery: comparing surgical groups and determining individual differences in postoperative sexuality and body change stress. J Consult Clin Psychol (2000) 1.21
Surgical-pathologic variables predictive of local recurrence in squamous cell carcinoma of the vulva. Gynecol Oncol (1990) 1.19
Psychosexual adjustment after vulvar surgery. Obstet Gynecol (1983) 1.19
Rhabdomyosarcoma of the uterine cervix. Sarcoma botryoides. Cancer (1987) 1.19
Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells. J Natl Cancer Inst (2001) 1.18
Survival of patients following secondary cytoreductive surgery in ovarian cancer. Obstet Gynecol (1983) 1.16
A distinct molecular profile associated with mucinous epithelial ovarian cancer. Br J Cancer (2006) 1.15
Current management of epithelial ovarian carcinoma: a review. Semin Surg Oncol (2000) 1.11
Management of regional lymph nodes and their prognostic influence in vulvar cancer. Obstet Gynecol (1983) 1.10
Psychological reactions to radiation therapy: reconsideration of the adaptive aspects of anxiety. J Pers Soc Psychol (1985) 1.09
Schemas, sexuality, and romantic attachment. J Pers Soc Psychol (1998) 1.07
Carcinoma of the cervix associated with pregnancy. Obstet Gynecol (1982) 1.06
Optimal management of endometrial hyperplasia. Best Pract Res Clin Obstet Gynaecol (2001) 1.04
OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal. Cancer (2001) 1.02
The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro. Br J Cancer (2008) 1.02
Physiologic and psychobehavioral research in oncology. Cancer (1991) 1.02
The case against aspirating ovarian cysts. Cancer (1993) 1.01
Attributions and adjustment to life-threatening illness. Br J Clin Psychol (1988) 1.01
Hormonal replacement therapy for postmenopausal women: a review of sexual outcomes and related gynecologic effects. Arch Sex Behav (1990) 1.00
Endometrial cancer in premenopausal women 45 years and younger. Obstet Gynecol (1995) 0.99
Intraperitoneal recombinant alpha-interferon for "salvage" immunotherapy in stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Cancer Res (1985) 0.99
Psychosexual adjustment following pelvic exenteration. Obstet Gynecol (1983) 0.99
Cytoreductive surgery in ovarian carcinoma: feasibility and morbidity. Obstet Gynecol (1986) 0.98
Anti-sense suppression of epidermal growth factor receptor expression alters cellular proliferation, cell-adhesion and tumorigenicity in ovarian cancer cells. Int J Cancer (2000) 0.98
Pharmacokinetics of Ip cisplatin in refractory ovarian carcinoma. Cancer Treat Rep (1983) 0.97
Sexual dysfunction and signs of gynecologic cancer. Cancer (1986) 0.97
Prognostic significance of DNA ploidy and morphometric analyses of adenocarcinoma of the uterine cervix. Anal Quant Cytol Histol (1987) 0.96
Malignant perivascular epithelioid cell tumor (PEComa) arising in the broad ligament. Int J Gynecol Cancer (2004) 0.96
Sexual functioning among breast cancer, gynecologic cancer, and healthy women. J Consult Clin Psychol (1985) 0.96
Epidemiology and etiology of ovarian cancer: a review. Obstet Gynecol (1985) 0.95
A comparison of systematic desensitization and directed masturbation in the treatment of primary orgasmic dysfunction in females. J Consult Clin Psychol (1981) 0.93
Nd: YAG laser therapy of rectosigmoid bleeding due to radiation injury. Obstet Gynecol (1982) 0.92
A randomized, multicentre study of directed daylight exposure times of 1½ vs. 2½ h in daylight-mediated photodynamic therapy with methyl aminolaevulinate in patients with multiple thin actinic keratoses of the face and scalp. Br J Dermatol (2011) 0.92
High frequency of allelic imbalance at regions of chromosome arm 8p in ovarian carcinoma. Cancer Genet Cytogenet (2001) 0.92
Primary carcinoma of the Bartholin gland: a report of 14 cases and review of the literature. Obstet Gynecol (1982) 0.91
Anxiety and cancer treatment: response to stressful radiotherapy. Health Psychol (1984) 0.91
A psychometric analysis of the sexual arousability index. J Consult Clin Psychol (1989) 0.90
Cervical carcinoma after negative Pap smears: evidence against rapid-onset cancers. Int J Gynecol Cancer (1992) 0.90
Central nervous system metastases in epithelial ovarian carcinoma. Cancer (1987) 0.89
The prevalence of group B streptococci in human urogenital secretions. Scand J Infect Dis (1979) 0.89
Preoperative radiation therapy for locally advanced vulvar cancer. Cancer (1984) 0.89
Estrogen and progesterone receptors in ovarian neoplasms. Gynecol Oncol (1983) 0.88
[Gonorrhoea in young women admitted to a gynaecology department]. Ugeskr Laeger (1974) 0.88
Hormone replacement therapy and risk of epithelial ovarian cancer. Br J Cancer (1999) 0.88
Surgery for invasive gynecologic cancer in the elderly female population. Obstet Gynecol (1990) 0.88
Estrogen and progesterone receptor sites in malignancies of the uterine cervix, vagina, and vulva. Gynecol Oncol (1983) 0.87
Risk factors for the development of lymph node metastasis in vulvar squamous cell carcinoma. Gynecol Oncol (1990) 0.87
Concurrent cisplatin and 5-fluorouracil chemotherapy and radiation therapy for advanced-stage squamous carcinoma of the vulva. Gynecol Oncol (1991) 0.87
Erythromelanosis follicularis faciei et colli. Case reports. Br J Dermatol (1980) 0.86
Individualization of treatment for stage I squamous cell vulvar carcinoma. Obstet Gynecol (1984) 0.85
Adenocarcinoma of the uterine cervix: histologic variables associated with lymph node metastasis and survival. Obstet Gynecol (1985) 0.85
Characterization of beta-hydroxybutyrate transport in rat erythrocytes and thymocytes. Biochim Biophys Acta (1978) 0.85
Squamous cell carcinoma of the vulva with bulky positive groin nodes-nodal debulking versus full groin dissection prior to radiation therapy. Int J Gynecol Cancer (2007) 0.84
Collagen and calcium-binding EGF domains 1 is frequently inactivated in ovarian cancer by aberrant promoter hypermethylation and modulates cell migration and survival. Br J Cancer (2009) 0.84
Laparoscopic port-site recurrence following surgery for a stage IB squamous cell carcinoma of the cervix with negative lymph nodes. Gynecol Oncol (2000) 0.84
Treatment of vulvar carcinoma in situ with the CO2 laser. Gynecol Oncol (1984) 0.84
Lymphatic ascites following lymphadenectomy for gynecological malignancy. Int J Gynecol Cancer (2001) 0.84
Rectosigmoid colectomy and reanastomosis to facilitate resection of primary and recurrent gynecologic cancer. Obstet Gynecol (1984) 0.83
Lower urinary tract resection as part of cytoreductive surgery for ovarian cancer. Gynecol Oncol (1982) 0.82
Patterns and trends of sexual behavior, HIV testing, and HIV prevalence among all sexually transmitted disease clinic attenders in Denmark. Sex Transm Dis (1997) 0.82
Hyperbaric oxygen therapy for delayed radiation injuries in gynecological cancers. Int J Gynecol Cancer (2006) 0.82
Clinical and operative staging of cervical cancer. Baillieres Clin Obstet Gynaecol (1988) 0.82
Controversies in the management of cervical adenocarcinoma. Obstet Gynecol (1988) 0.82
Superficially invasive vulvar cancer with nodal metastases. Gynecol Oncol (1983) 0.81
Yes, there are sexual problems. Now, what can we do about them? Gynecol Oncol (1994) 0.81
Spontaneous bowel haematoma with anticoagulant therapy. Med J Aust (1973) 0.81
Daylight-mediated photodynamic therapy of moderate to thick actinic keratoses of the face and scalp: a randomized multicentre study. Br J Dermatol (2012) 0.81
Influence of postoperative treatment on survival in patients with uterine papillary serous carcinoma. Gynecol Oncol (1998) 0.81
Microinvasive carcinoma of the vulva. Obstet Gynecol (1983) 0.81
Pancreatic and peripancreatic vessels: embolization for control of bleeding in pancreatitis. Radiology (1984) 0.81
Intraperitoneal immunotherapy of human ovarian carcinoma with Corynebacterium parvum. Cancer Res (1983) 0.80
Multimodality therapy for patients with clinical Stage I and II malignant mixed Müllerian tumors of the uterus. Cancer (2001) 0.80
Interleukin-6 (IL-6) does not change the expression of Bcl-2 protein in the prevention of cisplatin-induced apoptosis in ovarian cancer cell lines. J Obstet Gynaecol Res (1999) 0.80
Primary orgasmic dysfunction: diagnostic considerations and review of treatment. Psychol Bull (1983) 0.80
Lymphocyte cytotoxicity in the peritoneal cavity and blood of patients with ovarian cancer. Obstet Gynecol (1984) 0.80
Management of postexenteration perineal hernias by myocutaneous axial flaps. Gynecol Oncol (1982) 0.80
Corticosteroids in the management of bowel obstruction on a gynecological oncology unit. Gynecol Oncol (1999) 0.80
Granuloma annulare and diabetes mellitus. Clin Exp Dermatol (1979) 0.79
Whole abdominal radiation as salvage therapy for epithelial ovarian cancer. Obstet Gynecol (1985) 0.79
Clinicopathologic review of malignant polyps in stage 1A carcinoma of the endometrium. Gynecol Oncol (2005) 0.79
Malignancy arising in endometriosis associated with unopposed estrogen replacement. Obstet Gynecol (1988) 0.79
Peritoneal cytology of ovarian cancer patients receiving intraperitoneal therapy: quantitation of malignant cells and response. Obstet Gynecol (1988) 0.78
Current therapy for dysgerminoma of the ovary. Obstet Gynecol (1987) 0.78
Expression of cell regulatory proteins in ovarian borderline tumors. Cancer (1996) 0.78
Second-look laparotomy in stage III epithelial ovarian cancer: clinical variables associated with disease status. Obstet Gynecol (1984) 0.78
Protein kinase A-Ialpha subunit-directed antisense inhibition of ovarian cancer cell growth: crosstalk with tyrosine kinase signaling pathway. Oncogene (1999) 0.77
p53 protein overexpression: a strong prognostic factor in uterine papillary serous carcinoma. Gynecol Oncol (1998) 0.77
Long-term follow-up of patients with advanced ovarian carcinoma treated with chemotherapy. Ann Oncol (1993) 0.77